Switch theme
Sign up to access all valuation multiples
Sedana Medical AB is a Sweden-based medical technology company. It is a pioneer MedTech and pharmaceutical company focused on inhaled sedation to improve the patient’s life during and beyond sedation. The group's product range is Sedaconda ACD, Sedaconda, AnaConDa, FlurAbsorb, Gas Monitor, Adapters, and Accessories. The company operates in Sweden, Germany, Spain, Ireland, and France, out of which Germany accounts for the majority of the revenue.
2005
109
LTM Revenue $19.7M
LTM EBITDA -$2.4M
$106M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sedana Medical has a last 12-month revenue (LTM) of $19.7M and a last 12-month EBITDA of -$2.4M.
In the most recent fiscal year, Sedana Medical achieved revenue of $18.4M and an EBITDA of $1.4M.
Sedana Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sedana Medical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $19.7M | XXX | $18.4M | XXX | XXX | XXX |
| Gross Profit | $19.7M | XXX | $13.0M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 71% | XXX | XXX | XXX |
| EBITDA | -$2.4M | XXX | $1.4M | XXX | XXX | XXX |
| EBITDA Margin | -12% | XXX | 7% | XXX | XXX | XXX |
| EBIT | -$4.7M | XXX | -$5.2M | XXX | XXX | XXX |
| EBIT Margin | -24% | XXX | -28% | XXX | XXX | XXX |
| Net Profit | -$3.5M | XXX | -$1.1M | XXX | XXX | XXX |
| Net Margin | -18% | XXX | -6% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Sedana Medical's stock price is SEK 12 (or $1).
Sedana Medical has current market cap of SEK 1.2B (or $123M), and EV of SEK 1.0B (or $106M).
See Sedana Medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $106M | $123M | XXX | XXX | XXX | XXX | $-0.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Sedana Medical has market cap of $123M and EV of $106M.
Sedana Medical's trades at 5.8x EV/Revenue multiple, and 77.0x EV/EBITDA.
Equity research analysts estimate Sedana Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sedana Medical has a P/E ratio of -35.1x.
See valuation multiples for Sedana Medical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $123M | XXX | $123M | XXX | XXX | XXX |
| EV (current) | $106M | XXX | $106M | XXX | XXX | XXX |
| EV/Revenue | 5.4x | XXX | 5.8x | XXX | XXX | XXX |
| EV/EBITDA | -44.1x | XXX | 77.0x | XXX | XXX | XXX |
| EV/EBIT | -22.4x | XXX | -20.3x | XXX | XXX | XXX |
| EV/Gross Profit | 5.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -35.1x | XXX | -111.7x | XXX | XXX | XXX |
| EV/FCF | -14.7x | XXX | -5.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSedana Medical's last 12 month revenue growth is 15%
Sedana Medical's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Sedana Medical's rule of 40 is -6% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sedana Medical's rule of X is 26% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sedana Medical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Margin | -12% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Growth | -47% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -6% | XXX | 23% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 26% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 59% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 99% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sedana Medical acquired XXX companies to date.
Last acquisition by Sedana Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . Sedana Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sedana Medical founded? | Sedana Medical was founded in 2005. |
| Where is Sedana Medical headquartered? | Sedana Medical is headquartered in Sweden. |
| How many employees does Sedana Medical have? | As of today, Sedana Medical has 109 employees. |
| Who is the CEO of Sedana Medical? | Sedana Medical's CEO is Mr. Johannes Doll. |
| Is Sedana Medical publicy listed? | Yes, Sedana Medical is a public company listed on STO. |
| What is the stock symbol of Sedana Medical? | Sedana Medical trades under SEDANA ticker. |
| When did Sedana Medical go public? | Sedana Medical went public in 2017. |
| Who are competitors of Sedana Medical? | Similar companies to Sedana Medical include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Sedana Medical? | Sedana Medical's current market cap is $123M |
| What is the current revenue of Sedana Medical? | Sedana Medical's last 12 months revenue is $19.7M. |
| What is the current revenue growth of Sedana Medical? | Sedana Medical revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of Sedana Medical? | Current revenue multiple of Sedana Medical is 5.4x. |
| Is Sedana Medical profitable? | Yes, Sedana Medical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sedana Medical? | Sedana Medical's last 12 months EBITDA is -$2.4M. |
| What is Sedana Medical's EBITDA margin? | Sedana Medical's last 12 months EBITDA margin is -12%. |
| What is the current EV/EBITDA multiple of Sedana Medical? | Current EBITDA multiple of Sedana Medical is -44.1x. |
| What is the current FCF of Sedana Medical? | Sedana Medical's last 12 months FCF is -$7.2M. |
| What is Sedana Medical's FCF margin? | Sedana Medical's last 12 months FCF margin is -37%. |
| What is the current EV/FCF multiple of Sedana Medical? | Current FCF multiple of Sedana Medical is -14.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
